Utilizing Alvotech/Teva’s ustekinumab biosimilar, Navitus Health will begin offering its Lumicera Health-branded ustekinumab-aekn, beginning July 1, while excluding the reference product Stelara. The net price of this product is said to be approximately $1,000 per 90-mg dose, or more than a 90% discount from Stelara’s wholesale acquisition cost (WAC). Like the big 3 PBMs with … Continue reading Navitus Private-Label Ustekinumab Available July 1